209 related articles for article (PubMed ID: 22552893)
21. Antibiotic pressure is a major risk factor for rectal colonization by multidrug-resistant Pseudomonas aeruginosa in critically ill patients.
Gómez-Zorrilla S; Camoez M; Tubau F; Periche E; Cañizares R; Dominguez MA; Ariza J; Peña C
Antimicrob Agents Chemother; 2014 Oct; 58(10):5863-70. PubMed ID: 25049255
[TBL] [Abstract][Full Text] [Related]
22. Molecular characterization of extensively drug-resistant hypervirulent Pseudomonas aeruginosa isolates in China.
Li J; Tang M; Liu Z; Wei Y; Xia F; Xia Y; Hu Y; Wang H; Zou M
Ann Clin Microbiol Antimicrob; 2024 Feb; 23(1):13. PubMed ID: 38347529
[TBL] [Abstract][Full Text] [Related]
23. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
Sader HS; Huband MD; Castanheira M; Flamm RK
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
[No Abstract] [Full Text] [Related]
24. Investigation of a nosocomial outbreak by alginate-producing pan-antibiotic-resistant Pseudomonas aeruginosa.
Yakupogullari Y; Otlu B; Dogukan M; Gursoy C; Korkmaz E; Kizirgil A; Ozden M; Durmaz R
Am J Infect Control; 2008 Dec; 36(10):e13-8. PubMed ID: 19084158
[TBL] [Abstract][Full Text] [Related]
25. Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update.
Del Barrio-Tofiño E; López-Causapé C; Oliver A
Int J Antimicrob Agents; 2020 Dec; 56(6):106196. PubMed ID: 33045347
[TBL] [Abstract][Full Text] [Related]
26. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
[TBL] [Abstract][Full Text] [Related]
27. Interplay among Resistance Profiles, High-Risk Clones, and Virulence in the Caenorhabditis elegans Pseudomonas aeruginosa Infection Model.
Sánchez-Diener I; Zamorano L; López-Causapé C; Cabot G; Mulet X; Peña C; Del Campo R; Cantón R; Doménech-Sánchez A; Martínez-Martínez L; Arcos SC; Navas A; Oliver A
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923877
[TBL] [Abstract][Full Text] [Related]
28. Pseudomonas aeruginosa bacteremia in children over ten consecutive years: analysis of clinical characteristics, risk factors of multi-drug resistance and clinical outcomes.
Yang MA; Lee J; Choi EH; Lee HJ
J Korean Med Sci; 2011 May; 26(5):612-8. PubMed ID: 21532850
[TBL] [Abstract][Full Text] [Related]
29. Characteristics, risk factors and outcomes of adult cancer patients with extensively drug-resistant Pseudomonas aeruginosa infections.
Samonis G; Vardakas KZ; Kofteridis DP; Dimopoulou D; Andrianaki AM; Chatzinikolaou I; Katsanevaki E; Maraki S; Falagas ME
Infection; 2014 Aug; 42(4):721-8. PubMed ID: 24912861
[TBL] [Abstract][Full Text] [Related]
30. Distribution of carbapenem resistance mechanisms in clinical isolates of XDR Pseudomonas aeruginosa.
De Rosa A; Mutters NT; Mastroianni CM; Kaiser SJ; Günther F
Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1547-1552. PubMed ID: 31152264
[TBL] [Abstract][Full Text] [Related]
31. Pseudomonas aeruginosa bacteremia after burn injury: the impact of multiple-drug resistance.
Theodorou P; Thamm OC; Perbix W; Phan VT
J Burn Care Res; 2013; 34(6):649-58. PubMed ID: 23817000
[TBL] [Abstract][Full Text] [Related]
32. Biological markers of Pseudomonas aeruginosa epidemic high-risk clones.
Mulet X; Cabot G; Ocampo-Sosa AA; Domínguez MA; Zamorano L; Juan C; Tubau F; Rodríguez C; Moyà B; Peña C; Martínez-Martínez L; Oliver A;
Antimicrob Agents Chemother; 2013 Nov; 57(11):5527-35. PubMed ID: 23979744
[TBL] [Abstract][Full Text] [Related]
33. Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infection.
Viasus D; Puerta-Alcalde P; Cardozo C; Suárez-Lledó M; Rodríguez-Núñez O; Morata L; Fehér C; Marco F; Chumbita M; Moreno-García E; Fernández-Avilés F; Gutiérrez-Garcia G; Martínez JA; Mensa J; Rovira M; Esteve J; Soriano A; Garcia-Vidal C
Clin Microbiol Infect; 2020 Mar; 26(3):345-350. PubMed ID: 31295551
[TBL] [Abstract][Full Text] [Related]
34. High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial.
Pérez A; Gato E; Pérez-Llarena J; Fernández-Cuenca F; Gude MJ; Oviaño M; Pachón ME; Garnacho J; González V; Pascual Á; Cisneros JM; Bou G
J Antimicrob Chemother; 2019 May; 74(5):1244-1252. PubMed ID: 30753505
[TBL] [Abstract][Full Text] [Related]
35. Predictors of Mortality in Bloodstream Infections Caused by Pseudomonas aeruginosa and Impact of Antimicrobial Resistance and Bacterial Virulence.
Recio R; Mancheño M; Viedma E; Villa J; Orellana MÁ; Lora-Tamayo J; Chaves F
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767719
[TBL] [Abstract][Full Text] [Related]
36. Bacterial and clinical characteristics of health care- and community-acquired bloodstream infections due to Pseudomonas aeruginosa.
Hattemer A; Hauser A; Diaz M; Scheetz M; Shah N; Allen JP; Porhomayon J; El-Solh AA
Antimicrob Agents Chemother; 2013 Aug; 57(8):3969-75. PubMed ID: 23733476
[TBL] [Abstract][Full Text] [Related]
37. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia.
Morata L; Cobos-Trigueros N; Martínez JA; Soriano A; Almela M; Marco F; Sterzik H; Núñez R; Hernández C; Mensa J
Antimicrob Agents Chemother; 2012 Sep; 56(9):4833-7. PubMed ID: 22751533
[TBL] [Abstract][Full Text] [Related]
38. Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia.
Khawcharoenporn T; Chuncharunee A; Maluangnon C; Taweesakulvashra T; Tiamsak P
Int J Antimicrob Agents; 2018 Dec; 52(6):828-834. PubMed ID: 30236956
[TBL] [Abstract][Full Text] [Related]
39. Determinants for persistence of Pseudomonas aeruginosa in hospitals: interplay between resistance, virulence and biofilm formation.
Kaiser SJ; Mutters NT; DeRosa A; Ewers C; Frank U; Günther F
Eur J Clin Microbiol Infect Dis; 2017 Feb; 36(2):243-253. PubMed ID: 27734161
[TBL] [Abstract][Full Text] [Related]
40. Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology.
Del Barrio-Tofiño E; Zamorano L; Cortes-Lara S; López-Causapé C; Sánchez-Diener I; Cabot G; Bou G; Martínez-Martínez L; Oliver A;
J Antimicrob Chemother; 2019 Jul; 74(7):1825-1835. PubMed ID: 30989186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
